Biocept, Inc. (BIOC): Price and Financial Metrics

Biocept, Inc. (BIOC)

Today's Latest Price: $0.66 USD

0.04 (-5.21%)

Updated Jul 2 4:00pm

Add BIOC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BIOC Stock Summary

  • With a price/sales ratio of 15.69, Biocept Inc has a higher such ratio than 91.2% of stocks in our set.
  • With a year-over-year growth in debt of -33.61%, Biocept Inc's debt growth rate surpasses just 8.41% of about US stocks.
  • As for revenue growth, note that BIOC's revenue has grown 71.61% over the past 12 months; that beats the revenue growth of 92.42% of US companies in our set.
  • Stocks that are quantitatively similar to BIOC, based on their financial statements, market capitalization, and price volatility, are TTPH, APDN, XONE, SCWX, and CRTO.
  • BIOC's SEC filings can be seen here. And to visit Biocept Inc's official web site, go to
BIOC Daily Price Range
BIOC 52-Week Price Range

BIOC Stock Price Chart Technical Analysis Charts

BIOC Price/Volume Stats

Current price $0.66 52-week high $1.15
Prev. close $0.69 52-week low $0.21
Day low $0.64 Volume 10,473,772
Day high $0.69 Avg. volume 20,528,096
50-day MA $0.52 Dividend yield N/A
200-day MA $0.48 Market Cap 86.07M

BIOC Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BIOC Latest Social Stream

Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it has been awarded Canadian Patent 2812291, entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION. This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumor cells (CTCs), and from a biological fluid. The issuance of this patent increases Biocept's total patent awards for use in its molecular diagnostics business to 40.

Yahoo | June 30, 2020

Biocept’s Covid-19 Testing Capacity Puts It at the Head of the Pack

Unfortunately, the coronavirus isn’t going anywhere just yet, as the surge of infections in parts of the US shows no signs of slowing down. In many areas, the number of cases has continued to rise; Seven states — Arizona, Arkansas, California, North Carolina, South Carolina, Tennessee and Texas — reported the highest amount of hospitalizations since the pandemic’s onset.To help in the battle against COVID-19, diagnostics specialist Biocept (BIOC) has entered the fray. The micro-cap has manufactured 10,000 nasopharangeal swab collection kits, which will be available by 3Q to conduct PCR testing for COVID-19 in California.Maxim analyst Jason McCarthy believes “Biocept may be in the right place at the right time.”“The availability of Biocept's collection kits comes at a crucial time wh...

Yahoo | June 27, 2020

Biocept partners with managed care provider

Biocept (BIOC) is partnering with managed care provider, Medical Cost Containment Professionals, to process out-of-network claims for their liquid biopsy testing."MCCP's network includes 47M covered lives, with some members covered by multiple plans.  We are working to enter into additional similar partnerships that help adjudicate out-of-network claims, as well as...

Seeking Alpha | June 24, 2020

Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims

/PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable…

PR Newswire | June 24, 2020

Biocept's COVID-19 testing kit now available for physician ordering

Biocept (BIOC) announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for COVID-19 for physician ordering.Collected specimens will be shipped overnight to Biocept's, CLIA-certified and BSL-2 safety level laboratory in San Diego with results returned in an estimated 24 to 48 hours. Biocept-developed RT-PCR COVID-19 kits are expected...

Seeking Alpha | June 22, 2020

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo 50.86%
3-mo 134.04%
6-mo 97.13%
1-year -36.54%
3-year -98.41%
5-year -99.72%
YTD 130.77%
2019 -66.74%
2018 -95.85%
2017 -10.39%
2016 -81.40%
2015 -44.35%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.898 seconds.